These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 31902406)
1. Renal Impairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran. Zijlstra LE; Trompet S; Mooijaart SP; van Buren M; Jukema JW Mayo Clin Proc; 2020 Jan; 95(1):12-14. PubMed ID: 31902406 [No Abstract] [Full Text] [Related]
2. Inclisiran for the treatment of dyslipidemia. Nishikido T; Ray KK Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410 [TBL] [Abstract][Full Text] [Related]
3. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. Ray KK; Landmesser U; Leiter LA; Kallend D; Dufour R; Karakas M; Hall T; Troquay RP; Turner T; Visseren FL; Wijngaard P; Wright RS; Kastelein JJ N Engl J Med; 2017 Apr; 376(15):1430-1440. PubMed ID: 28306389 [TBL] [Abstract][Full Text] [Related]
4. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. Leiter LA; Teoh H; Kallend D; Wright RS; Landmesser U; Wijngaard PLJ; Kastelein JJP; Ray KK Diabetes Care; 2019 Jan; 42(1):173-176. PubMed ID: 30487231 [TBL] [Abstract][Full Text] [Related]
5. Cholesterol lowering with inclisiran: a new chapter in the PCSK9 story book. Santos RD; Rocha VZ Eur Heart J; 2023 Jan; 44(2):139-141. PubMed ID: 36331316 [No Abstract] [Full Text] [Related]
6. Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk. Santulli G; Jankauskas SS; Gambardella J Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):e11-e12. PubMed ID: 33655296 [No Abstract] [Full Text] [Related]
7. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1. Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484 [TBL] [Abstract][Full Text] [Related]
8. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype? Hadjiphilippou S; Ray KK Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304 [TBL] [Abstract][Full Text] [Related]
9. Inclisiran: A Game Changer in a Changing Game? Nambi V; Agha A J Am Coll Cardiol; 2021 Mar; 77(9):1194-1196. PubMed ID: 33663736 [No Abstract] [Full Text] [Related]
10. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748 [TBL] [Abstract][Full Text] [Related]
11. New hope for hyperlipidemia management: Inclisiran. Bandyopadhyay D; Hajra A; Ashish K; Qureshi A; Ball S J Cardiol; 2018 May; 71(5):523-524. PubMed ID: 29174841 [No Abstract] [Full Text] [Related]
12. PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. Page MM; Watts GF Diabetes Obes Metab; 2018 Feb; 20(2):270-282. PubMed ID: 28736830 [TBL] [Abstract][Full Text] [Related]
13. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. Fitzgerald K; White S; Borodovsky A; Bettencourt BR; Strahs A; Clausen V; Wijngaard P; Horton JD; Taubel J; Brooks A; Fernando C; Kauffman RS; Kallend D; Vaishnaw A; Simon A N Engl J Med; 2017 Jan; 376(1):41-51. PubMed ID: 27959715 [TBL] [Abstract][Full Text] [Related]
14. RNA Interference for the Masses? siRNA Targeting PCSK9 Promises Prevention of Cardiovascular Disease. Watts JK; Ockene IS Nucleic Acid Ther; 2020 Feb; 30(1):1-3. PubMed ID: 31928497 [No Abstract] [Full Text] [Related]